ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,629.00
0.55%
S&P ASX All Technology
3,016.30
1.48%
Brent Oil
82.765
0.00%
US Dollar vs AUD
1.514
-0.05%
Bitcoin
63,467.60
0.92%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Nymox Pharmaceutical Corp (NYMX)

  7. Nymox Pharmaceutical Corp (NYMX) News

NYMX

Nymox Pharmaceutical (NYMX)

Nymox Pharmaceutical Corp
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NYMX
DateTimeSourceHeadlineSymbolCompany
29/03/202404:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
10/11/202304:55Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
07/11/202301:59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
27/10/202306:31Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
09/09/202300:13Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:NYMXNymox Pharmaceutical Corp
30/08/202305:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
03/08/202303:40Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
01/08/202303:54Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
26/07/202306:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
26/07/202306:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
26/07/202300:33GlobeNewswire Inc.Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial ResultsNASDAQ:NYMXNymox Pharmaceutical Corp
19/07/202300:45GlobeNewswire Inc.Nymox Reports on U.S. Patent IssuancesNASDAQ:NYMXNymox Pharmaceutical Corp
14/07/202300:16GlobeNewswire Inc.Nymox UpdateNASDAQ:NYMXNymox Pharmaceutical Corp
13/07/202307:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
12/07/202323:30GlobeNewswire Inc.Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of NymoxNASDAQ:NYMXNymox Pharmaceutical Corp
08/07/202307:02GlobeNewswire Inc.NYMOX UpdateNASDAQ:NYMXNymox Pharmaceutical Corp
06/07/202308:11GlobeNewswire Inc.Nymox Delisting from NASDAQNASDAQ:NYMXNymox Pharmaceutical Corp
30/06/202307:15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NYMXNymox Pharmaceutical Corp
30/06/202307:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:NYMXNymox Pharmaceutical Corp
30/06/202306:25Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:NYMXNymox Pharmaceutical Corp
30/06/202306:24Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:NYMXNymox Pharmaceutical Corp
28/06/202307:15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NYMXNymox Pharmaceutical Corp
27/06/202300:28Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:NYMXNymox Pharmaceutical Corp
19/05/202306:14Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:NYMXNymox Pharmaceutical Corp
13/05/202306:53Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:NYMXNymox Pharmaceutical Corp
11/05/202300:00GlobeNewswire Inc.Nymox Provides Current UpdateNASDAQ:NYMXNymox Pharmaceutical Corp
03/04/202323:30GlobeNewswire Inc.Nymox Provides Corporate UpdateNASDAQ:NYMXNymox Pharmaceutical Corp
01/04/202307:25Edgar (US Regulatory)Notification That Form 20-f Will Be Submitted Late (nt 20-f)NASDAQ:NYMXNymox Pharmaceutical Corp
22/03/202301:00GlobeNewswire Inc.Nymox Announces Appointment of Christopher R. Riley as Chief Financial OfficerNASDAQ:NYMXNymox Pharmaceutical Corp
16/03/202300:30GlobeNewswire Inc.Nymox Officially Granted Extension to Regain Listing RequirementsNASDAQ:NYMXNymox Pharmaceutical Corp
 Showing the most relevant articles for your search:NASDAQ:NYMX

Your Recent History

COIN
ETHUSD
Ethereum
ASX
ANZ
Australia And New Zealan...
NYSE
MCD
McDonalds
CCOM
SILVER
SILVER
NASDAQ
AAPL
Apple
FX
GBPAUD
Sterling vs AUD
NYSE
MRK
Merck
ASX
WES
Wesfarmers
ASX
SUN
Suncorp
NYSE
KO
Coca Cola
ASX
CBA
Commonwealth Bank Of Aus...
PM
XAUUSD
Gold vs US Dollar
ASX
FMG
Fortescue
FX
AUDCAD
AUD vs CAD
FTSE
UKX
FTSE 100
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved